New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Worldwide, RSV infections lead to more than three million hospitalisations and almost 60,000 deaths in children under five years of ... 3 MELODY trial, a phase 2/3 study called MEDLEY and an ...

Paediatricians have identified some visible signs in children that indicate a growth failure and requires medical intervention to reverse, particularly in children under the age of five years.

In May 2025, a rumor began to spread online that Japan had ended all vaccinations for children under 24 months, leading infant mortality to drop by 96%. Meanwhile, the infant mortality rate ...